A male in his seventies presented with multiple erythematous follicular papules on the back, followed by lesions in the occipital region and posterior neck. Fungal examination revealed kerion celsi caused by Trichophyton rubrum. The patient was treated with fosravuconazole 100 mg/day for 8 weeks, and the brush method was negative 1 month later. The oral antifungal medicines approved for treatment of tinea capitis in Japan are limited to itraconazole and terbinafine hydrochloride. However, itraconazole has many contraindicated drugs, and antifungal resistance has recently become a major concern.As the challenge of drug-resistant fungi is expected to become more significant in the future, the clinical benefits of using fosravuconazole L-lysine ethanolate (F-RVCZ) for treating kerion celsi may increase. Our experience suggests that F-RVCZ could be a valuable therapeutic option.

We herein report the first case of tinea capitis caused by Trichophyton tonsurans that responded to fosravuconazole (F-RVCZ). Clinical improvement was achieved within six weeks after the start of F-RVCZ therapy, and the hairbrush culture test was negative. After treatment discontinuation, no relapse of symptoms was observed, and subsequent hairbrush cultures remained negative. F-RVCZ has been suggested as a rapidly acting and effective therapeutic agent for tinea capitis caused by this infection. Treatment of tinea capitis requires oral antifungal therapy; however, side effects associated with long-term administration sometimes occur. Oral treatment with F-RVCZ was found to be effective and had the advantage of relatively few side effects.

We encountered a 60-year-old Japanese female patient with disseminated dermatophytosis caused by terbinafine-resistant Trichophyton rubrum with mutant SQLE (Leu393Phe substitution). Histopathology showed fungus in the dermis, indicating Majocchi granuloma. Oral fosravuconazole and topical luliconazole were administered for 18 months, resulting in invasive dermatophytosis with a high β-d-glucan level of 7320 pg/mL. The MICs of amphotericin B, posaconazole, griseofulvin, itraconazole, voriconazole, ravuconazole, and terbinafine were 0.5, 0.5, 8, 16, 8, 16, and 32 μg/mL, respectively. Amphotericin B for 6 months followed by oral posaconazole for another 6 months cured the disease. Posaconazole may be a promising agent for the treatment of multidrug-resistant dermatophytes. We present the first reported case of multiazole-resistant T. rubrum resulting from prolonged fosravuconazole treatment.

We herein report the first case of tinea capitis caused by Trichophyton tonsurans that responded to fosravuconazole (F-RVCZ). Clinical improvement was achieved within six weeks after the start of F-RVCZ therapy, and the hairbrush culture test was negative. After treatment discontinuation, no relapse of symptoms was observed, and subsequent hairbrush cultures remained negative. F-RVCZ has been suggested as a rapidly acting and effective therapeutic agent for tinea capitis caused by this infection. Treatment of tinea capitis requires oral antifungal therapy; however, side effects associated with long-term administration sometimes occur. Oral treatment with F-RVCZ was found to be effective and had the advantage of relatively few side effects.

A man in his thirties patient visited his previous physician with the chief complaint of a pigmented macule on the sole of his left foot that had steadily grown over the past two years. A dermoscopic examination of the lesion showed a parallel ridge pattern (PRP); therefore, acral-lentiginous melanoma (ALM) was suspected, and the patient was referred to our hospital for a more detailed examination. On closer inspection, PRP had a well-defined and irregular border with no variation in color, which is atypical for ALM which is characterized by asymmetrical structure and variation in colors. Therefore, a skin biopsy was performed for a definite diagnosis, and the histopathological findings showed mycelia in the horny layers. Fungal culture revealed Hortaea werneckii, and the patient was diagnosed with tinea nigra (TN). Although TN is a rare fungal infection in Japan, we emphasize that this fungal infection should be noted as a mimic of ALM and should be considered when PRP is detected on the palms and soles by dermoscopic examination.

Multi-antifungal-resistant strains of Trichophyton indotineae and Trichophyton rubrum have been isolated in Japan. In the present study, we examined the in vitro susceptibility of terbinafine (TRBF) -resistant isolates of T. indotineae and T. rubrum to efinaconazole (EFCZ) and luliconazole (LUCZ). In all isolates, the minimum inhibitory concentrations were ≥ 32 mg/l for TRBF, < 0.03 to 16 mg/l for itraconazole, < 0.03 to 16 mg/l for ravuconazole, < 0.03 to 0.5 mg/l for LUCZ, and < 0.03 to 4 mg/l for EFCZ. Of note, T. rubrum NUBS21012 and T. indotineae NUBS 19006T showed resistance to LUCZ and/or EFCZ unlike the other isolates.

Dear Editor, As a consequence of the COVID19 pandemic, skin disorders associated with maskwearing and washing hands, such as acne and dermatitis, have increased, becoming a social issue.1,2 We encountered a patient with atypical cutaneous candidiasis in the area covered by her mask. We herein report the first welldocumented case of cutaneous candidiasis with useful dermoscopic findings. Six months before presentation, a 13yearold girl exhibited erythema around her lips. Despite treatment with topical steroids and antimicrobial agents, there was no improvement, so she visited our department. She showed welldemarcated scaly erythema on her left cheek due to maskrelated friction. We detected reddish papules and some whitish scales at the upper and lower lips. No rash was observed in the oral cavity, tongue, or mouth angle (Figure 1a– c). Suspecting intractable eczema on the cheeks, we performed a skin biopsy. Dermoscopy revealed whitish, irregular, scaly areas with a small central yellow crust on the cheek (Figure 1d). On the chin, which was less scaly, there were multiple small pustules and small, round, whitish structures, both surrounded by a reddish halo (Figure 1e). The small, round structures appeared to correspond to small pustules. However, neither closed nor open comedones, a characteristic symptom of acne, were detected. A potassium hydroxide (KOH) examination revealed numerous pseudohyphae and spores (Figure 1f). Rapidly growing creamy colonies were isolated on a Mycosel agar medium, and green colonies formed on CHROMagerTM Candida medium. A biopsy of the rash on the left cheek revealed filamentous pseudohyphae in the stratum corneum with periodic acidSchiff staining, neutrophil infiltration in the epidermis, mild interface damage, and marked lymphocyte infiltration around the dermal capillaries (Figure 1g). A genetic search showed the causative organism to be Candida albicans. She was successfully treated with topical ketoconazole cream and oral fosravuconazole.

A dermatophyte antigen kit (DQT) was released in Japan as an in vitro diagnostic tool to identify tinea unguium in June 2022. From July 2022 to February 2023, we examined 75 potassium hydroxide (KOH)-negative patients (male, n = 23; female, n = 52; mean ± SD age, 63.6 ± 13.9 years) and determined the accuracy in confirming the fungal element with ZoomBlue™ staining at 400× magnification. The DQT results were classified into three categories. DQT-positive onychomycosis was detected in 27 patients with tinea unguium and two with non-dermatophyte onychomycosis. Fungal cultures were positive in 14 (51.8%) patients (Trichophyton rubrum [n = 11], T. interdigitale [n = 1], Fusarium solani [n = 1], and Talaromyces muroii [n = 1]). DQT-negative onychomycosis included ten patients with cured tinea unguium and 3 with Candida onychomycosis. Twenty-three patients had DQT-negative mimics for onychomycosis (onychauxis [n = 11], traumatic onycholysis [n = 8], yellow nail syndrome [n = 5], pincer nail deformity [n = 3], brittle nail syndrome [n = 2], contact dermatitis [n = 2], lichen planus [n = 1] and psoriasis [n = 1]). Because sparse, atrophic and/or fragmented mycelia are invisible in direct microscopy with potassium hydroxide (KOH) at 100× magnification, DQT was beneficial for diagnosing onychomycosis.

Scopulariopsis brevicaulis is commonly found in soil and on surfaces exposed to the air, attacking a great variety of organic materials growing on substances rich in protein. This particular species, S. brevicaulis, is well recognized as the most common etiologic agent of non-dermatophyte onychomycosis in temperate zones.1 Antifungal therapy with itraconazole and terbinafine is less effective than that in dermatophytosis.2 We herein report a definitive case of onychomycosis caused by S. brevicaulis. A 44-year-old female homemaker with no particular history or underlying disease, including tinea pedis and tinea unguium, noticed brown discoloration of her right big toenail 3 years previously. Upon presentation in February 2019, the nail was thickened (2.3 mm) with a cinnamon-colored surface. The clinical subtype was distal and lateral subungual onychomycosis (Figure 1a). Direct microscopy of a nail specimen revealed numerous thick-walled oval- or lemon-shaped conidia with a truncated base (Figure 1c). Histopathologically, periodic acid–Schiff staining showed septate hyphae and conidia (Figure 1d). Plate culture on Sabouraud’s dextrose agar at 25°C yielded a buff-colored, powdery colony with radial grooves after 4 weeks. The colony reverse was a pale yellow-brown (Figure 1e). Slide cultures revealed verticillate annellidic conidiophores with basipetal conidial chains (Figure 1f). The base sequence of the internal transcribed spacer region of the isolate’s rRNA gene showed 99% (609/611bp) homology with the S. brevicaulis ex-type strain MUCL 40726 (GenBank accession: LM652465). We identified this isolate as S. brevicaulis (Sacc.) Bainier, deposited in Chiba University as IFM 65758. Oral fosravuconazole 100 mg/daily for 2 months and the topical application of 10% efinaconazole solution for 3 months were partially effective (Figure 1b). Antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute M38-A2 protocol. The minimum inhibitory concentrations (MIC) at the first visit for ravuconazole, itraconazole, and terbinafine were 8, >32, and 0.125 µg/mL, whereas after treatment with fosravuconazole, the MIC for itraconazole, terbinafine, fosravuconazole, efinaconazole, luliconazole, amorolfine, ketoconazole, and voriconazole were >16, 4.0, 2.0, 0.13, 0.002, 40.5, 4.0, and 16 µg/mL, respectively. Regrettably the patient ceased to visit our clinic after that, and attempts to contact her in any way, such by phone or mail, were unsuccessful. The members of the genus Scopulariopsis are cosmopolitan, and five species have been associated with human disease: S. brevicaulis, S. brumptii, S. acremonium, S. fusca, and S. konigii. The genus Microascus was referred to as a teleomorph of S. brevicaulis: Microascus brevicaulis.1 Notably, this case is the fourth reported patient in Japan,3 following a case in 2018.4 Scopulariopsis brevicaulis is characterized by intrinsic resistance to broad-spectrum antifungal agents. Our case had no history of any antifungal treatment. The molecular mechanisms of resistance mainly involve substitution in the azole target (lanosterol 14-α-demethylase) and/or an overexpression of this gene and/or efflux pumps.5 MIC for itraconazole, terbinafine, and voriconazole were >16, 4, and >16 µg/mL, respectively.2 In our strain, the MIC for fosravuconazole, efinaconazole, and luliconazole were 2.0, 0.13, and 0.002, respectively, suggesting that oral fosravuconazole and the topical application of efinaconazole and luliconazole might be effective for S. brevicaulis onychomycosis. This work was partly supported by the Japan Agency for Medical Research and Development, AMED under grant number JP21fk0108094. None declared.

The Journal of DermatologyVolume 46, Issue 12 p. e446-e447 Letter to the Editor Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole Hiromitsu Noguchi, Corresponding Author Hiromitsu Noguchi derma@nogcli.jp orcid.org/0000-0003-4993-304X Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanCorrespondence: Hiromitsu Noguchi, M.D., Ph.D., Noguchi Dermatology Clinic, 1834-1 Namazu, Kashima-machi, Kamimashiki-gun, Kumamoto 861-3101, Japan. Email: derma@nogcli.jpSearch for more papers by this authorTadahiko Matsumoto, Tadahiko Matsumoto Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorMasataro Hiruma, Masataro Hiruma Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorUtako Kimura, Utako Kimura orcid.org/0000-0002-9217-1805 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this authorRui Kano, Rui Kano orcid.org/0000-0003-1764-629X Department of Veterinary Pathobiology, Nihon University College of Bioresource Sciences, Kanagawa, JapanSearch for more papers by this authorTakashi Yaguchi, Takashi Yaguchi Division of Bio-resources, Medical Mycology Research Center, Chiba University, Chiba, JapanSearch for more papers by this authorSatoshi Fukushima, Satoshi Fukushima orcid.org/0000-0002-0622-7682 Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanSearch for more papers by this authorHironobu Ihn, Hironobu Ihn Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanSearch for more papers by this author Hiromitsu Noguchi, Corresponding Author Hiromitsu Noguchi derma@nogcli.jp orcid.org/0000-0003-4993-304X Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanCorrespondence: Hiromitsu Noguchi, M.D., Ph.D., Noguchi Dermatology Clinic, 1834-1 Namazu, Kashima-machi, Kamimashiki-gun, Kumamoto 861-3101, Japan. Email: derma@nogcli.jpSearch for more papers by this authorTadahiko Matsumoto, Tadahiko Matsumoto Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorMasataro Hiruma, Masataro Hiruma Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorUtako Kimura, Utako Kimura orcid.org/0000-0002-9217-1805 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this authorRui Kano, Rui Kano orcid.org/0000-0003-1764-629X Department of Veterinary Pathobiology, Nihon University College of Bioresource Sciences, Kanagawa, JapanSearch for more papers by this authorTakashi Yaguchi, Takashi Yaguchi Division of Bio-resources, Medical Mycology Research Center, Chiba University, Chiba, JapanSearch for more papers by this authorSatoshi Fukushima, Satoshi Fukushima orcid.org/0000-0002-0622-7682 Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanSearch for more papers by this authorHironobu Ihn, Hironobu Ihn Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanSearch for more papers by this author First published: 29 July 2019 https://doi.org/10.1111/1346-8138.15033Citations: 16Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume46, Issue12December 2019Pages e446-e447 RelatedInformation

Nannizzia gypsea, previously known as Microsporum gypseum, is a geophilic dermatophyte that infects humans from the soil. We isolated N. gypsea from a two-year-old girl with kerion celsi. Because of her serious medical condition, she was admitted to the pediatric ward immediately after birth. We struggled to identify the route of infection, and eventually identified her grandmother's handmade belt, which covered the endotracheal-tube-holding device, as the infection source. To prevent indirect transmission of pathogenic microorganisms from outside the hospital environment, our hospital prohibited the bringing of belongings from outside.

We encountered two cases of phaeohyphomycosis caused by Exophiala jeanselmei and E. oligosperma that were treated with fosravuconazole and terbinafine, respectively. Our cases were successfully treated with empiric therapy before the pathogen's species or antifungal sensitivity had been determined. We summarized 32 cases of cutaneous and subcutaneous phaeohyphomycosis caused by Exophiala species in Japan. The patients received antifungals, including itraconazole, terbinafine, voriconazole, and fosravuconazole, and the treatment success rates of these monotherapies were 77% (17/22), 67% (8/12), 100% (5/5), and 50% (1/2), respectively. Although the broad-spectrum azole antifungal itraconazole is the first choice for treatment, terbinafine at 125 mg/day might exert the same efficacy. Fosravuconazole is a novel broad-spectrum azole and a moderate inhibitor of Cyp3A4 that causes fewer drug interactions than itraconazole and voriconazole, indicating a promising drug for this disease.

The multi-antifungal drug-resistant strain (NUBS21012) of Trichophyton rubrum was isolated from a patient with recurrent tinea corporis. The resistant strain encoded Phe at codon 393 instead of Leu (L393F) in the squalene epoxidase (SQLE) gene. The expression of genes encoding ATP-binding cassette transporter proteins increased in the strain compared to that of other strains. This result provides evidence that ATP-binding cassette transporter proteins are closely associated with azole resistance.

Dear Editor, The genus Penicillium, which contains over 300 species, is an ascomycetous fungal group that is part of the mycobiome of many species and is of major importance in the natural environment, food spoilage, and food and drug production. Most species are encountered as contaminants. Some infrequently appear as human pathogens.1 Exceptionally, Talaromyces marneffei (Penicillium marneffei) is a human dimorphic pathogenic fungus.1 Occasionally, Penicillium species have been reported to cause onychomycosis; however, the species epithets were rarely stated or inadequately described.2 We report the first documented case of onychomycosis caused by Penicillium citrinum. A 66yearold healthy female homemaker visited our clinic in October 2017. She had noticed white and brown discoloration on her left big toenail 1 year previously (Figure 1a). Although oral terbinafine for 12 months resulted in remission and cured the tinea unguium of her right big toenail, the lesion recurred in January 2019. The clinical subtype was proximal subungual onychomycosis (Figure 1b). Although the clinical subtype was the same, the lesion may have initially demonstrated a mixed infection with dermatophytes (Figure 1a). Direct microscopy of the nail specimen revealed septate hyphae, pigmented and hyaline conidia, and metulae (Figure 1c). Histopathologically, periodic acid– Schiff staining showed mycelium and conidia (Figure 1d). Plate culture on Sabouraud’s dextrose agar at 25°C for 2 weeks yielded a greyish greencolored floccose colony with radial grooves with a paleyellow reverse (Figure 1e). Slide culture revealed biverticillate conidiogenesis containing metulae, phialides, and conidia (Figure 1f). The base sequence of the internal transcribed spacer region of the rRNA and βtubulin genes of the isolate were identical to Penicillium citrinum NRRL 1841NT (GenBank accession no.: AF033422, homology: 514/514 bp) and P. citrinum ATCC 9849 (KU897000, 445/445 bp), respectively. We deposited our P. citrinum isolates as IFM 65759. The diagnosis was ungual hyalohyphomycosis caused by P. citrinum. Antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute M38A2 protocol. The minimum inhibitory concentrations (MIC) for amorolfine, efinaconazole, itraconazole, ketoconazole, luliconazole, ravuconazole, terbinafine, and voriconazole were >16, 0.25, 0.5, 2.0, 0.00098, ≤0.015, 0.5, and >16 μg/mL, respectively. After 2month

The Journal of DermatologyVolume 48, Issue 7 p. e331-e332 LETTER TO THE EDITOR Tinea capitis caused by Trichophyton violaceum successfully treated with fosravuconazole Ayaka Miyata, orcid.org/0000-0001-9011-5300 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this authorUtako Kimura, Corresponding Author utako@juntendo.ac.jp orcid.org/0000-0002-9217-1805 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan Correspondence Utako Kimura, Department of Dermatology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba 279-0021, Japan. Email: utako@juntendo.ac.jpSearch for more papers by this authorHiromitsu Noguchi, orcid.org/0000-0003-4993-304X Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorTadahiko Matsumoto, Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorMasataro Hiruma, Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorRui Kano, orcid.org/0000-0003-1764-629X Department of Veterinary Dermatology, Nihon University College of Bioresource Sciences, Kanagawa, JapanSearch for more papers by this authorKenji Takamori, orcid.org/0000-0002-0644-0504 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this authorYasushi Suga, orcid.org/0000-0003-3643-2879 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this author Ayaka Miyata, orcid.org/0000-0001-9011-5300 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this authorUtako Kimura, Corresponding Author utako@juntendo.ac.jp orcid.org/0000-0002-9217-1805 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan Correspondence Utako Kimura, Department of Dermatology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu, Chiba 279-0021, Japan. Email: utako@juntendo.ac.jpSearch for more papers by this authorHiromitsu Noguchi, orcid.org/0000-0003-4993-304X Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorTadahiko Matsumoto, Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorMasataro Hiruma, Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorRui Kano, orcid.org/0000-0003-1764-629X Department of Veterinary Dermatology, Nihon University College of Bioresource Sciences, Kanagawa, JapanSearch for more papers by this authorKenji Takamori, orcid.org/0000-0002-0644-0504 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this authorYasushi Suga, orcid.org/0000-0003-3643-2879 Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this author First published: 15 April 2021 https://doi.org/10.1111/1346-8138.15901Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume48, Issue7July 2021Pages e331-e332 RelatedInformation

Society for Publication of Acta Dermato-Venereologica Terbinafine, which targets squalene epoxidase (SQLE), has been used to treat dermatophyte infections for approximately 30 years. In 2017, a Swiss study reported that 1% (16/1,644) of Trichophyton rubrum and 0.2% (1/412) of T. interdigitale were resistant to terbinafine (1). In 2019, we presented the first Japanese case of tinea unguium caused by a terbinafine-resistant T. rubrum isolate (Phe397Leu substitution), which was deposited as IFM 65760 (2). Our clinic obtained 3 terbinafine-resistant T. rubrum strains (Leu393Phe substitution) from 95 dermatophyte clinical isolates including T. rubrum (n = 62) and T. interdigitale (n = 33) in June 2020 (3). One strain (T. rubrum N79) was derived from a group home for individuals with intellectual disabilities. In this study, we examined the residents of this facility using mycological and molecular techniques to detect terbinafine-resistant T. rubrum strains.

The Journal of DermatologyVolume 47, Issue 7 p. e251-e253 Letter to the Editor Ungual hyalohyphomycosis caused by Fusarium proliferatum successfully treated with fosravuconazole Hiromitsu Noguchi, Corresponding Author Hiromitsu Noguchi derma@nogcli.jp orcid.org/0000-0003-4993-304X Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, Japan Correspondence: Hiromitsu Noguchi, M.D., Ph.D., Noguchi Dermatology Clinic, 1834-1 Namazu, Kashima-machi, Kamimashiki-gun, Kumamoto 861-3101, Japan. Email: derma@nogcli.jpSearch for more papers by this authorTadahiko Matsumoto, Tadahiko Matsumoto Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorUtako Kimura, Utako Kimura orcid.org/0000-0002-9217-1805 Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, Japan Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this authorMasataro Hiruma, Masataro Hiruma Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorRui Kano, Rui Kano orcid.org/0000-0003-1764-629X Department of Veterinary Pathobiology, Nihon University College of Bioresource Sciences, Kanagawa, JapanSearch for more papers by this authorTakashi Yaguchi, Takashi Yaguchi Division of Bio-resources, Medical Mycology Research Center, Chiba University, Chiba, JapanSearch for more papers by this authorSatoshi Fukushima, Satoshi Fukushima orcid.org/0000-0002-0622-7682 Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanSearch for more papers by this authorHironobu Ihn, Hironobu Ihn Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanSearch for more papers by this author Hiromitsu Noguchi, Corresponding Author Hiromitsu Noguchi derma@nogcli.jp orcid.org/0000-0003-4993-304X Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, Japan Correspondence: Hiromitsu Noguchi, M.D., Ph.D., Noguchi Dermatology Clinic, 1834-1 Namazu, Kashima-machi, Kamimashiki-gun, Kumamoto 861-3101, Japan. Email: derma@nogcli.jpSearch for more papers by this authorTadahiko Matsumoto, Tadahiko Matsumoto Noguchi Dermatology Clinic, Kumamoto, Japan Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorUtako Kimura, Utako Kimura orcid.org/0000-0002-9217-1805 Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, Japan Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, JapanSearch for more papers by this authorMasataro Hiruma, Masataro Hiruma Ochanomizu Institute for Medical Mycology and Allergology, Tokyo, JapanSearch for more papers by this authorRui Kano, Rui Kano orcid.org/0000-0003-1764-629X Department of Veterinary Pathobiology, Nihon University College of Bioresource Sciences, Kanagawa, JapanSearch for more papers by this authorTakashi Yaguchi, Takashi Yaguchi Division of Bio-resources, Medical Mycology Research Center, Chiba University, Chiba, JapanSearch for more papers by this authorSatoshi Fukushima, Satoshi Fukushima orcid.org/0000-0002-0622-7682 Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanSearch for more papers by this authorHironobu Ihn, Hironobu Ihn Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, JapanSearch for more papers by this author First published: 28 April 2020 https://doi.org/10.1111/1346-8138.15358Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume47, Issue7July 2020Pages e251-e253 RelatedInformation